Literature DB >> 23932924

MicroRNA-106a induces multidrug resistance in gastric cancer by targeting RUNX3.

Yi Zhang1, Qiping Lu, Xun Cai.   

Abstract

Multidrug resistance (MDR) is the main barrier to the success of chemotherapy for gastric cancer (GC). miR-106a, which is highly expressed in GC, influences a variety of aspects of GC. However, the function of miR-106a in MDR of GC still remains unclear. In the present study, we found that miR-106a is elevated in MDR cell lines. miR-106a promotes chemo-resistance of GC cells, accelerates ADR efflux, and suppresses drug-induced apoptosis. Finally, we show that runt-related trans factor 3 (RUNX3) is the functional target of miR-106a. Collectively, these findings demonstrate that miR-106a may promote MDR in GC cells by targeting RUNX3.
Copyright © 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Gastric cancer; Multidrug resistance; Runt-related transcription factor 3; miR-106a

Mesh:

Substances:

Year:  2013        PMID: 23932924     DOI: 10.1016/j.febslet.2013.06.058

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  34 in total

Review 1.  Interaction between gastric cancer stem cells and the tumor microenvironment.

Authors:  Takatsugu Ishimoto; Hiroshi Sawayama; Hidetaka Sugihara; Hideo Baba
Journal:  J Gastroenterol       Date:  2014-03-21       Impact factor: 7.527

Review 2.  Non-coding RNAs underlying chemoresistance in gastric cancer.

Authors:  Arash Poursheikhani; Zahra Bahmanpour; Ehsan Razmara; Ladan Mashouri; Mohammad Taheri; Dorsa Morshedi Rad; Hassan Yousefi; Amirreza Bitaraf; Sadegh Babashah
Journal:  Cell Oncol (Dordr)       Date:  2020-06-03       Impact factor: 6.730

3.  The Profile of Serum microRNAs Predicts Prognosis for Resected Gastric Cancer Patients Receiving Platinum-Based Chemotherapy.

Authors:  Jianning Song; Jie Yin; Zhigang Bai; Jun Zhang; Hua Meng; Jun Cai; Wei Deng; Xuemei Ma; Zhongtao Zhang
Journal:  Dig Dis Sci       Date:  2017-03-24       Impact factor: 3.199

4.  miR-106a suppresses tumor cells death in colorectal cancer through targeting ATG7.

Authors:  Haibin Hao; Guangfeng Xia; Chao Wang; Fuping Zhong; Laipeng Liu; Dong Zhang
Journal:  Med Mol Morphol       Date:  2016-12-15       Impact factor: 2.309

5.  MiR-143 suppresses osteogenic differentiation by targeting Osterix.

Authors:  Enqi Li; Jinli Zhang; Tianxiang Yuan; Baotong Ma
Journal:  Mol Cell Biochem       Date:  2014-01-01       Impact factor: 3.396

Review 6.  How to stomach an epigenetic insult: the gastric cancer epigenome.

Authors:  Nisha Padmanabhan; Toshikazu Ushijima; Patrick Tan
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-05-17       Impact factor: 46.802

7.  Decreased MicroRNA-26a expression causes cisplatin resistance in human non-small cell lung cancer.

Authors:  Yong Yang; Peng Zhang; Yanfeng Zhao; Jie Yang; Gening Jiang; Jie Fan
Journal:  Cancer Biol Ther       Date:  2015-10-22       Impact factor: 4.742

8.  MiR-195 inhibits the growth and metastasis of NSCLC cells by targeting IGF1R.

Authors:  Xiaoli Wang; Yuchang Wang; Hongwen Lan; Jun Li
Journal:  Tumour Biol       Date:  2014-05-30

9.  Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance.

Authors:  Katia Danza; Nicola Silvestris; Giovanni Simone; Michele Signorile; Luca Saragoni; Oronzo Brunetti; Manlio Monti; Annalisa Mazzotta; Simona De Summa; Anita Mangia; Stefania Tommasi
Journal:  Cancer Biol Ther       Date:  2016-04-02       Impact factor: 4.742

10.  MiR-218 inhibits multidrug resistance (MDR) of gastric cancer cells by targeting Hedgehog/smoothened.

Authors:  Xiang-Liang Zhang; Hui-Juan Shi; Ji-Ping Wang; Hong-Sheng Tang; Shu-Zhong Cui
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.